FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2957827266> ?p ?o ?g. }

• W2957827266 endingPage "985" @default.
• W2957827266 startingPage "985" @default.
• W2957827266 abstract "We hypothesized that sorafenib plus transarterial chemoembolization (TACE) would confer survival benefits over sorafenib alone for advanced hepatocellular carcinoma (aHCC). We investigated this while using the population-based All-Cancer Dataset to assemble a cohort (n = 3674; median age, 60; 83% men) of patients receiving sorafenib for aHCC (Child-Pugh A) with macro-vascular invasion or nodal/distant metastases. The patients were classified into the sorafenib-TACE group (n = 426) or the propensity score-matched sorafenib-alone group (n = 1686). All of the participants were followed up until death or the end of the study. Time-dependent Cox model and the Mantel–Byar test were used for survival analysis. During the median follow-ups of 221 and 133 days for the sorafenib-TACE and sorafenib-alone groups, 164 (39%) and 916 (54%) deaths occurred, respectively; the corresponding median overall survivals (OS) were 381 and 204 days, respectively (hazard ratio, HR: 0.74; 95% confidence interval, CI, 0.63–0.88; p = 0.021). The one-year and six-month OS were 53.5% and 80.3% in the sorafenib-TACE group and 32.4% and 54.4% in the sorafenib-alone group, respectively. The major complications were comparable between the two groups. The addition of TACE to sorafenib improves survival, with a 26% reduction in mortality. These findings provide strong real-world evidence that supports this combination strategy for eligible Child-Pugh A aHCC patients." @default.
• W2957827266 created "2019-07-23" @default.
• W2957827266 creator A5012556372 @default.
• W2957827266 creator A5027297185 @default.
• W2957827266 creator A5035002114 @default.
• W2957827266 creator A5037553213 @default.
• W2957827266 creator A5056278493 @default.
• W2957827266 creator A5070107141 @default.
• W2957827266 creator A5071424104 @default.
• W2957827266 date "2019-07-15" @default.
• W2957827266 modified "2023-10-18" @default.
• W2957827266 title "Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study" @default.
• W2957827266 cites W1528399298 @default.
• W2957827266 cites W1586421535 @default.
• W2957827266 cites W1601002325 @default.
• W2957827266 cites W1971837077 @default.
• W2957827266 cites W1983151239 @default.
• W2957827266 cites W1994193851 @default.
• W2957827266 cites W1996703005 @default.
• W2957827266 cites W2003664440 @default.
• W2957827266 cites W2033679365 @default.
• W2957827266 cites W2084416450 @default.
• W2957827266 cites W2111464526 @default.
• W2957827266 cites W2128370577 @default.
• W2957827266 cites W2132006978 @default.
• W2957827266 cites W2138029572 @default.
• W2957827266 cites W2156538729 @default.
• W2957827266 cites W2162741760 @default.
• W2957827266 cites W2166585031 @default.
• W2957827266 cites W2168041959 @default.
• W2957827266 cites W2168997800 @default.
• W2957827266 cites W2169252033 @default.
• W2957827266 cites W2225797292 @default.
• W2957827266 cites W2227197023 @default.
• W2957827266 cites W2270417004 @default.
• W2957827266 cites W2272675209 @default.
• W2957827266 cites W2295189237 @default.
• W2957827266 cites W2343849531 @default.
• W2957827266 cites W2560154684 @default.
• W2957827266 cites W2560499218 @default.
• W2957827266 cites W2560688864 @default.
• W2957827266 cites W2584708577 @default.
• W2957827266 cites W2602458679 @default.
• W2957827266 cites W2661307008 @default.
• W2957827266 cites W2751349726 @default.
• W2957827266 cites W2802614347 @default.
• W2957827266 cites W2889646458 @default.
• W2957827266 cites W2902109874 @default.
• W2957827266 cites W4210955410 @default.
• W2957827266 cites W2728264314 @default.
• W2957827266 doi "https://doi.org/10.3390/cancers11070985" @default.
• W2957827266 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6679028" @default.
• W2957827266 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31311148" @default.
• W2957827266 hasPublicationYear "2019" @default.
• W2957827266 type Work @default.
• W2957827266 sameAs 2957827266 @default.
• W2957827266 citedByCount "30" @default.
• W2957827266 countsByYear W29578272662020 @default.
• W2957827266 countsByYear W29578272662021 @default.
• W2957827266 countsByYear W29578272662022 @default.
• W2957827266 countsByYear W29578272662023 @default.
• W2957827266 crossrefType "journal-article" @default.
• W2957827266 hasAuthorship W2957827266A5012556372 @default.
• W2957827266 hasAuthorship W2957827266A5027297185 @default.
• W2957827266 hasAuthorship W2957827266A5035002114 @default.
• W2957827266 hasAuthorship W2957827266A5037553213 @default.
• W2957827266 hasAuthorship W2957827266A5056278493 @default.
• W2957827266 hasAuthorship W2957827266A5070107141 @default.
• W2957827266 hasAuthorship W2957827266A5071424104 @default.
• W2957827266 hasBestOaLocation W29578272661 @default.
• W2957827266 hasConcept C126322002 @default.
• W2957827266 hasConcept C143998085 @default.
• W2957827266 hasConcept C17923572 @default.
• W2957827266 hasConcept C207103383 @default.
• W2957827266 hasConcept C2778019345 @default.
• W2957827266 hasConcept C2778695046 @default.
• W2957827266 hasConcept C2908647359 @default.
• W2957827266 hasConcept C44249647 @default.
• W2957827266 hasConcept C50382708 @default.
• W2957827266 hasConcept C71924100 @default.
• W2957827266 hasConcept C72563966 @default.
• W2957827266 hasConcept C90924648 @default.
• W2957827266 hasConcept C99454951 @default.
• W2957827266 hasConceptScore W2957827266C126322002 @default.
• W2957827266 hasConceptScore W2957827266C143998085 @default.
• W2957827266 hasConceptScore W2957827266C17923572 @default.
• W2957827266 hasConceptScore W2957827266C207103383 @default.
• W2957827266 hasConceptScore W2957827266C2778019345 @default.
• W2957827266 hasConceptScore W2957827266C2778695046 @default.
• W2957827266 hasConceptScore W2957827266C2908647359 @default.
• W2957827266 hasConceptScore W2957827266C44249647 @default.
• W2957827266 hasConceptScore W2957827266C50382708 @default.
• W2957827266 hasConceptScore W2957827266C71924100 @default.
• W2957827266 hasConceptScore W2957827266C72563966 @default.
• W2957827266 hasConceptScore W2957827266C90924648 @default.
• W2957827266 hasConceptScore W2957827266C99454951 @default.
• W2957827266 hasFunder F4320322795 @default.
• W2957827266 hasIssue "7" @default.

• next